These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Human and chimpanzee monoclonal antibodies.
    Author: Van Meel FC, Steenbakkers PG, Oomen JC.
    Journal: J Immunol Methods; 1985 Jun 25; 80(2):267-76. PubMed ID: 2989374.
    Abstract:
    Monoclonal antibody-secreting cell lines were isolated after transformation of peripheral blood leukocytes with Epstein-Barr virus. Blood samples were obtained from human donors having circulating antibodies against hepatitis viruses (HAB, HBV), rubella, or rabies virus and from a chimpanzee infected with HAV. Dextran-isolated leukocytes were submitted to Epstein-Barr virus infection at low cell concentrations (1 X 10(4) cells X ml-1). Proliferating clones could be observed in 50-100% of the cultures within 4-6 weeks. Out of 1 ml blood (1 X 10(6) leukocytes) 1-10 stable clones were isolated, secreting specific anti-viral antibodies. These clones were fused with an aminopterin-sensitive, ouabain-resistant, non-immunoglobulin producing mouse-human hybridoma (Org MHH.1). From such fusions 10-90% of the cultures yielded viable hybridomas of which 45% produced antibodies with the same specificity as of the parental EBV transformant. Immunoglobulin production of both EBV transformants and hybridomas was shown to be stable for more than 6 months and at a concentration up to 100 micrograms X ml-1 X 48 h-1. Chimpanzee EBV-transformed lymphocytes proliferated excellently in vitro. Mouse-human hybridomas, however, could be more easily cultivated, cloned and scaled up than the parental EBV-transformed lymphocytes. In conclusion, stable, monoclonal antibody-secreting cell lines of either human or chimpanzee origin could be isolated with an efficiency that exceeds by 10-100-fold standard murine hybridoma technology.
    [Abstract] [Full Text] [Related] [New Search]